癌症免疫疗法的个性化观点。
A personalized view on cancer immunotherapy.
作者信息
Wayteck Laura, Breckpot Karine, Demeester Jo, De Smedt Stefaan C, Raemdonck Koen
机构信息
Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.
Laboratory of Molecular and Cellular Therapy, Department of Immunology and Physiology, Medical School of the Vrije Universiteit Brussel, Laarbeeklaan 103/E, 1090 Brussels, Belgium.
出版信息
Cancer Lett. 2014 Sep 28;352(1):113-25. doi: 10.1016/j.canlet.2013.09.016. Epub 2013 Sep 17.
Recent progress in cancer immunotherapy has resulted in complete responses in patients refractory to current standard cancer therapies. However, due to tumor heterogeneity and inter-individual variations in anti-tumor immunity, only subsets of patients experience clinical benefit. This review highlights the implementation of a personalized approach to enhance treatment efficacy and reduce side effects, including the identification of tumor-specific antigens for cancer vaccination and adoptive T cell therapies. Furthermore, together with the current advances and promising clinical outcomes of combination cancer (immuno-)therapies, the screening for predictive biomarkers in a patient-specific manner is emphasized.
癌症免疫疗法的最新进展已使对当前标准癌症疗法难治的患者实现了完全缓解。然而，由于肿瘤异质性和抗肿瘤免疫的个体差异，只有部分患者能从临床治疗中获益。本综述重点介绍了采用个性化方法提高治疗效果并减少副作用，包括识别用于癌症疫苗接种和过继性T细胞疗法的肿瘤特异性抗原。此外，结合联合癌症（免疫）疗法的当前进展和有前景的临床结果，强调了以患者特异性方式筛选预测性生物标志物。
Zotero 插件